Niklas Mattsson1,2,3, Nicholas C Cullen4,5, Ulf Andreasson5,6, Henrik Zetterberg5,6,7,8, Kaj Blennow5,6. 1. Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden. 2. Department of Neurology, Skåne University Hospital, Sweden. 3. Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden. 4. Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 5. Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 6. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 7. Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, United Kingdom. 8. UK Dementia Research Institute at University College London, London, United Kingdom.
Abstract
Importance: Plasma neurofilament light (NfL) has been suggested as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking. Objective: To examine whether longitudinal plasma NfL levels are associated with other hallmarks of AD. Design, Setting, and Participants: This North American cohort study used data from 1583 individuals in the multicenter Alzheimer's Disease Neuroimaging Initiative study from September 7, 2005, through June 16, 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018. Exposures: Clinical diagnosis, Aβ and tau cerebrospinal fluid (CSF) biomarkers, imaging measures (magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography), and tests on cognitive scores. Main Outcomes and Measures: The primary outcome was the association between baseline exposures (diagnosis, CSF biomarkers, imaging measures, and cognition) and longitudinal plasma NfL levels, analyzed by an ultrasensitive assay. The secondary outcomes were the associations between a multimodal classification scheme with Aβ, tau, and neurodegeneration (ie, the ATN system) and plasma NfL levels and between longitudinal changes in plasma NfL levels and changes in the other measures. Results: Of the included 1583 participants, 716 (45.2%) were women, and the mean (SD) age was 72.9 (7.1) years; 401 had no cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P < .001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. A longitudinal increase in NfL level correlated with baseline CSF biomarkers (low Aβ42 [P = .001], high total tau [P = .02], and high phosphorylated tau levels [P = .02]), magnetic resonance imaging measures (small hippocampal volumes [P < .001], thin regional cortices [P = .009], and large ventricular volumes [P = .002]), low fluorodeoxyglucose-positron emission tomography uptake (P = .01), and poor cognitive performance (P < .001) for a global cognitive score. With use of the ATN system, increased baseline NfL levels were seen in A-T+N+ (P < .001), A+T-N+ (P < .001), and A+T+N+ (P < .001), and increased rates of NfL levels were seen in A-T+N- (P = .009), A-T+N+ (P = .02), A+T-N+ (P = .04), and A+T+N+ (P = .002). Faster increase in NfL levels correlated with faster increase in CSF biomarkers of neuronal injury, faster rates of atrophy and hypometabolism, and faster worsening in global cognition (all P < .05 in patients with mild cognitive impairment; associations differed slightly in cognitively unimpaired controls and patients with AD dementia). Conclusions and Relevance: The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.
Importance: Plasma neurofilament light (NfL) has been suggested as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking. Objective: To examine whether longitudinal plasma NfL levels are associated with other hallmarks of AD. Design, Setting, and Participants: This North American cohort study used data from 1583 individuals in the multicenter Alzheimer's Disease Neuroimaging Initiative study from September 7, 2005, through June 16, 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018. Exposures: Clinical diagnosis, Aβ and tau cerebrospinal fluid (CSF) biomarkers, imaging measures (magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography), and tests on cognitive scores. Main Outcomes and Measures: The primary outcome was the association between baseline exposures (diagnosis, CSF biomarkers, imaging measures, and cognition) and longitudinal plasma NfL levels, analyzed by an ultrasensitive assay. The secondary outcomes were the associations between a multimodal classification scheme with Aβ, tau, and neurodegeneration (ie, the ATN system) and plasma NfL levels and between longitudinal changes in plasma NfL levels and changes in the other measures. Results: Of the included 1583 participants, 716 (45.2%) were women, and the mean (SD) age was 72.9 (7.1) years; 401 had no cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P < .001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. A longitudinal increase in NfL level correlated with baseline CSF biomarkers (low Aβ42 [P = .001], high total tau [P = .02], and high phosphorylated tau levels [P = .02]), magnetic resonance imaging measures (small hippocampal volumes [P < .001], thin regional cortices [P = .009], and large ventricular volumes [P = .002]), low fluorodeoxyglucose-positron emission tomography uptake (P = .01), and poor cognitive performance (P < .001) for a global cognitive score. With use of the ATN system, increased baseline NfL levels were seen in A-T+N+ (P < .001), A+T-N+ (P < .001), and A+T+N+ (P < .001), and increased rates of NfL levels were seen in A-T+N- (P = .009), A-T+N+ (P = .02), A+T-N+ (P = .04), and A+T+N+ (P = .002). Faster increase in NfL levels correlated with faster increase in CSF biomarkers of neuronal injury, faster rates of atrophy and hypometabolism, and faster worsening in global cognition (all P < .05 in patients with mild cognitive impairment; associations differed slightly in cognitively unimpaired controls and patients with AD dementia). Conclusions and Relevance: The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.
Authors: G M De Marchis; M Katan; C Barro; J Fladt; C Traenka; D J Seiffge; L Hert; H Gensicke; G Disanto; R Sutter; N Peters; H Sarikaya; B Goeggel-Simonetti; M El-Koussy; S Engelter; P A Lyrer; M Christ-Crain; M Arnold; J Kuhle; L H Bonati Journal: Eur J Neurol Date: 2018-01-24 Impact factor: 6.089
Authors: Clifford R Jack; Josephine Barnes; Matt A Bernstein; Bret J Borowski; James Brewer; Shona Clegg; Anders M Dale; Owen Carmichael; Christopher Ching; Charles DeCarli; Rahul S Desikan; Christine Fennema-Notestine; Anders M Fjell; Evan Fletcher; Nick C Fox; Jeff Gunter; Boris A Gutman; Dominic Holland; Xue Hua; Philip Insel; Kejal Kantarci; Ron J Killiany; Gunnar Krueger; Kelvin K Leung; Scott Mackin; Pauline Maillard; Ian B Malone; Niklas Mattsson; Linda McEvoy; Marc Modat; Susanne Mueller; Rachel Nosheny; Sebastien Ourselin; Norbert Schuff; Matthew L Senjem; Alix Simonson; Paul M Thompson; Dan Rettmann; Prashanthi Vemuri; Kristine Walhovd; Yansong Zhao; Samantha Zuk; Michael Weiner Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Clifford R Jack; Matt A Bernstein; Nick C Fox; Paul Thompson; Gene Alexander; Danielle Harvey; Bret Borowski; Paula J Britson; Jennifer L Whitwell; Chadwick Ward; Anders M Dale; Joel P Felmlee; Jeffrey L Gunter; Derek L G Hill; Ron Killiany; Norbert Schuff; Sabrina Fox-Bosetti; Chen Lin; Colin Studholme; Charles S DeCarli; Gunnar Krueger; Heidi A Ward; Gregory J Metzger; Katherine T Scott; Richard Mallozzi; Daniel Blezek; Joshua Levy; Josef P Debbins; Adam S Fleisher; Marilyn Albert; Robert Green; George Bartzokis; Gary Glover; John Mugler; Michael W Weiner Journal: J Magn Reson Imaging Date: 2008-04 Impact factor: 4.813
Authors: Marion Moseby-Knappe; Niklas Mattsson; Niklas Nielsen; Henrik Zetterberg; Kaj Blennow; Josef Dankiewicz; Irina Dragancea; Hans Friberg; Gisela Lilja; Philip S Insel; Christian Rylander; Erik Westhall; Jesper Kjaergaard; Matt P Wise; Christian Hassager; Michael A Kuiper; Pascal Stammet; Michael C Jaeger Wanscher; Jørn Wetterslev; David Erlinge; Janneke Horn; Tommaso Pellis; Tobias Cronberg Journal: JAMA Neurol Date: 2019-01-01 Impact factor: 18.302
Authors: Niklas Mattsson; Michael Schöll; Olof Strandberg; Ruben Smith; Sebastian Palmqvist; Philip S Insel; Douglas Hägerström; Tomas Ohlsson; Henrik Zetterberg; Jonas Jögi; Kaj Blennow; Oskar Hansson Journal: EMBO Mol Med Date: 2017-09 Impact factor: 12.137
Authors: Yakeel T Quiroz; Henrik Zetterberg; Eric M Reiman; Yinghua Chen; Yi Su; Joshua T Fox-Fuller; Gloria Garcia; Andres Villegas; Diego Sepulveda-Falla; Marina Villada; Joseph F Arboleda-Velasquez; Edmarie Guzmán-Vélez; Clara Vila-Castelar; Brian A Gordon; Stephanie A Schultz; Hillary D Protas; Valentina Ghisays; Margarita Giraldo; Victoria Tirado; Ana Baena; Claudia Munoz; Silvia Rios-Romenets; Pierre N Tariot; Kaj Blennow; Francisco Lopera Journal: Lancet Neurol Date: 2020-05-26 Impact factor: 44.182
Authors: Júlia Faura; Alejandro Bustamante; Anna Penalba; Dolors Giralt; Alba Simats; Elena Martínez-Sáez; Daniel Alcolea; Juan Fortea; Alberto Lleó; Charlotte E Teunissen; Wiesje M van der Flier; Laura Ibañez; Oscar Harari; Carlos Cruchaga; Mar Hernández-Guillamón; Pilar Delgado; Joan Montaner Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Matthew P Pase; Jayandra J Himali; Alexa S Beiser; Charles DeCarli; Emer R McGrath; Claudia L Satizabal; Hugo J Aparicio; Hieab H H Adams; Alexander P Reiner; W T Longstreth; Myriam Fornage; Russell P Tracy; Oscar Lopez; Bruce M Psaty; Daniel Levy; Sudha Seshadri; Joshua C Bis Journal: Neurology Date: 2019-12-09 Impact factor: 9.910